Close Menu

NGAL

The assays measure biomarkers — NGAL and KIM-1 — that the company said will help drug developers gauge the right dose for drugs in Phase I trials, validate proof-of-concept in Phase II, and confirm efficacy and safety in Phase III studies by helping avoid kidney damage in participants.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.